Apotex Corporation, a US-based company involved in generic pharmaceuticals and biosimilars, announced on Tuesday that it has introduced Teriparatide Injection, a single-patient-use pre-filled pen intended for the treatment of osteoporosis, in the US.
Teriparatide Injection is supplied as a single-patient-use pre-filled pen containing 250 mcg/mL, capable of administering 28 daily doses of 20 mcg per pen.
Michael Bohling, Apotex Corp vice president of Sales and Marketing, said: "Osteoporosis impacts approximately 10 million Americans, and millions more have low bone density, placing them at high risk. The launch of this product will provide much-needed affordable access for these patients."
Kiran Krishnan, PhD, Apotex Corp senior vice president of Global Regulatory Affairs, also commented: "The approval of Teriparatide Injection is a testament to Apotex's commitment to the development of complex generic drugs and ensures expanded access for patients to affordable, high-quality medicines."
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
Emmaus Life Sciences names new chief executive officer
Sun Pharma finalises Taro acquisition
Biocon seeking partner to test semaglutide generics in China
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Lutris Pharma names new director
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia